• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Pro-Dex Inc.

    10/17/23 5:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care
    Get the next $PDEX alert in real time by email
    SC 13D 1 pdex_monogram13d.htm SCHEDULE 13D

     

     

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ___)*

     

    Monogram Orthopaedics Inc.
    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    609786108

    (CUSIP Number)

     

    Alisha Charlton

    c/o Pro-Dex, Inc.

    2361 McGaw Avenue

    Irvine, CA 92614

    949-769-3231

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    October 6, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

    _______________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     
     

     

    CUSIP Number  609786108 SCHEDULE 13D Page 2 of 7

     

     

     

    1

    NAME OF REPORTING PERSON

     

    Pro-Dex, Inc.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ¨
    (b) ¨
    3

    SEC USE ONLY

     

     
    4

    SOURCE OF FUNDS

     

    WC

     
    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

    ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Colorado

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

     

    1,828,551

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    1,828,551

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON

     

    1,828,551

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.9% (1)

     
    14

    TYPE OF REPORTING PERSON

     

    CO

     

     

    (1)Percentage calculated on the basis of 31,131,191 shares of common stock, par value $0.001 per share (“Common Stock”), of Monogram Orthopaedics Inc., a Delaware corporation (the “Issuer”), outstanding as of October 2, 2023, as reported by the Issuer on its Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (“SEC”) on October 6, 2023.

     

     

     
     
    CUSIP Number  609786108 SCHEDULE 13D Page 3 of 7

     

     

     

     Item 1. Security and Issuer.

     

    This Statement of Beneficial Ownership on Schedule 13D (this “Statement”) relates to the Common Stock of the Issuer. The address of the Issuer's principal executive offices is 3919 Todd Lane, Austin, TX 78744.

     

    Item 2. Identity and Background.

     

    This Statement is filed by Pro-Dex, Inc., a Colorado corporation (the “Reporting Person”). The Investment Committee of the Reporting Person exercises voting and dispositive power with respect to the Common Stock subject to this Statement. The Investment Committee of the Reporting Person consists of Raymond E. Cabillot, Nicholas J. Swenson and Richard L. Van Kirk. Since the Investment Committee of the Reporting Person exercises voting and dispositive power with respect to the shares, each of the foregoing individuals disclaims any beneficial ownership of the shares held by the Reporting Person.

     

    The principal business of the Reporting Person is the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and craniomaxillofacial (“CMF”) markets.

     

    The principal business address of the Reporting Person is 2361 McGaw Avenue, Irvine, California 92614.

     

    The following table sets forth the name and present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted of each director and executive officer of the Reporting Person (each of such directors and officers, a “Covered Person” and collectively, the “Covered Persons”). The business address of each such person is c/o Pro-Dex, Inc., 2361 McGaw Avenue, Irvine, California, 92614. Each Covered Person is a citizen of the United States of America.

     

    Name Principal Occupation
    Raymond E. Cabillot

    Director of the Reporting Person

    Chief Executive Officer and Director of Farnam Street Capital, Inc., the general partner of Farnam Street Partners L.P., a private investment partnership

    Farnam Street Capital, Inc.

    3033 Excelsior Boulevard, Suite 560

    Minneapolis, MN 55426

     

    Director of Air T, Inc., a provider of air cargo services and ground equipment sales and support services

     

    Air T, Inc.

    11020 David Taylor Drive, Suite 305

    Charlotte, North Carolina 28262

    Angelita R. Domingo

    Director of Quality Systems and Regulatory Affairs and Director of the Reporting Person

     

     

    William J. Farrell III

    Director of the Reporting Person

     

    SVP of Business Services at Gundersen Health System, an integrated healthcare organization

     

    Gundersen Health System

    1900 South Ave.

    La Crosse, WI 54601

     

    Chief Executive Officer of Viszy Inc., a company developing software and services for the consumer market

     

    Viszy Inc.

    2919 Hennepin Avenue

    Minneapolis, MN 55408

     

     

     

     
     
    CUSIP Number  609786108 SCHEDULE 13D Page 4 of 7

     

     

     

    David C. Hovda

    Director of the Reporting Person

     

    Founder of MedTech Advisors LLC

    Katrina M.K. Philp

    Director of the Reporting Person

     

    Chief of Staff of Air T, Inc., a provider of air cargo services and ground equipment sales and support services

     

    Air T, Inc.

    11020 David Taylor Drive, Suite 305

    Charlotte, North Carolina 28262

    Nicholas J. Swenson

    Director and Chairman of the Board of the Reporting Person

     

    Managing partner of AO Partners, LLC, the general partner of AO Partners I, L.P., a private investment partnership

     

    AO Partners, LLC

    5000 West 36th Street, Suite 130

    Minneapolis, MN 55416

     

    President, Chief Executive Officer Director and Chairman of the Board of Air T, Inc., a provider of air cargo services and ground equipment sales and support services

     

    Air T, Inc.

    11020 David Taylor Drive, Suite 305

    Charlotte, North Carolina 28262

    Richard L. Van Kirk

    Director, Chief Executive Officer, President and Chief Operating Officer of the Reporting Person

     

    Director of the Issuer

     

    Monogram Orthopaedics Inc.

    3919 Todd Lane

    Austin, TX 78744

    Alisha K. Charlton Chief Financial Officer of the Reporting Person

     

    Each of the Reporting Person and, to the Reporting Person’s knowledge, the Covered Persons have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    Each of the Reporting Person and, to the Reporting Person’s knowledge, the Covered Persons have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     
     
    CUSIP Number  609786108 SCHEDULE 13D Page 5 of 7

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    On December 20, 2018, the Reporting Person was issued a warrant from the Issuer (the “Warrant”) to purchase (collectively, the “Warrant Shares”): (i) shares of each class or series of preferred stock of the Issuer outstanding on the date or dates of exercise (“Preferred Stock”), up to an aggregate amount for each such class or series equal to five percent (5%) (calculated on a post-exercise basis) of the total issued and outstanding number of Preferred Stock of such class or series; plus (ii) shares of Common Stock equal to five percent (5%) (calculated on a post-exercise basis) of the fully-diluted capitalization as of the date or dates of exercise; provided, that any shares of Preferred Stock that the Warrant has been or may be exercised for, as of the time of calculation, shall be excluded for purposes of determining fully-diluted capitalization. The aggregate exercise price for the Warrant Shares equaled $1,250,000.

     

    The Reporting Person and the Issuer subsequently entered into a letter agreement (the “Exercise Letter”), with an effective date of October 2, 2023, pursuant to which the Reporting Person agreed to exercise the Warrant in exchange for, among other things, a contingent right to receive additional warrants (each, an “Additional Warrant”) to purchase five percent (5%) (calculated on a post-exercise basis) of certain Qualified Future Issuances (as defined below) of securities by the Issuer. “Qualified Future Issuances” means any and all issuances of securities by the Issuer during the period between October 2, 2023 to December 31, 2025 (other than securities issued under the Issuer’s equity incentive plans), which during a Warrant Coverage Measurement Period (as defined in the Exercise Letter, and which generally represent staggered six-month periods) results in the Issuer receiving, or having the right to receive, gross proceeds of $5,000,000 or more during the Warrant Coverage Measurement Period. Any Additional Warrant will have a term of six (6) months from the date of issuance and an aggregate exercise price equal to the total gross proceeds received by the Issuer over the Warrant Coverage Measurement Period divided by the number of securities issued by the Issuer during the Warrant Coverage Measurement Period. The Exercise Letter also grants the Reporting Person “piggyback” registration rights for all securities of the Issuer from time to time owned by the Reporting Person on terms at least as favorable to the Reporting Person as the Issuer may at any time grant “piggyback” (or equivalent) registration rights to any other holder of securities of the Issuer. The foregoing description of the Exercise Letter does not purport to be complete and is qualified in its entirety by reference to the Exercise Letter filed as Exhibit 99.1 to this Statement, which is incorporated by reference herein.

     

    Upon its exercise of the Warrant pursuant to the Exercise Letter, the Reporting Person was issued 1,828,551 shares of Common Stock of the Issuer (with an issuance effective date of October 2, 2023) for payment of the $1,250,000 exercise price to the Issuer. The funds for payment of the exercise price were from the Reporting Person’s working capital.

     

     
     
    CUSIP Number  609786108 SCHEDULE 13D Page 6 of 7

     

     

     

    Item 4. Purpose of Transaction.

     

    The Reporting Person acquired the Common Stock to which this Statement relates in the ordinary course of business for investment purposes.

     

    The Reporting Person’s response to Item 3 of this Statement is incorporated by reference into this Item 4.

     

    Other than as described above, the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Person may change its purpose or formulate different plans or proposals with respect thereto at any time.

     

    Item 5. Interest in Securities of the Issuer.

     

    (a) The Reporting Person beneficially holds in the aggregate 1,828,551 shares of Common Stock, which represents approximately 5.9% of the Issuer’s outstanding shares of Common Stock. The Reporting Person directly holds the shares of Common Stock disclosed as beneficially owned by it in this Statement.

     

    The percentage ownership of shares of Common Stock set forth in this Statement is based on the 31,131,191 shares of Common Stock reported by the Issuer as outstanding as of October 2, 2023 in the Issuer’s Definitive Proxy Statement on Schedule 14A filed with the SEC on October 6, 2023.

     

    (b) The Reporting Person beneficially owns, and has the sole power to direct the voting and disposition of, the shares of Common Stock disclosed as beneficially owned by Reporting Person in this Statement.

     

    (c) Except as disclosed herein, the Reporting Person has not effected any other transactions in the securities of the Issuer during the past 60 days.

     

    (d) No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, the Common Stock beneficially owned by the Reporting Person.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    The Reporting Person’s response to Item 3 of this Statement is incorporated by reference into this Item 6.

     

    Richard L. Van Kirk, the Chief Executive Officer, President, Chief Operating Officer and a director of the Reporting Person, is a director of the Issuer.

     

    In conjunction with the Exercise Letter, the Reporting Person and the Issuer entered into a supply agreement pursuant to which the Reporting Person will manufacture and supply certain products to the Issuer.

     

    Except as otherwise set forth in this Statement, there are no contracts, arrangements, understandings or relationships among the Reporting Person or any of its directors or executive officers or between such persons and any other person with respect to any securities of the Issuer.  

     

    Item 7. Material to Be Filed as Exhibits.

     

      Exhibit 99.1 Letter Agreement to Monogram Orthopaedics Inc. dated October 2, 2023

     

      

     
     
    CUSIP Number  609786108 SCHEDULE 13D Page 7 of 7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

     

    Dated: October 17, 2023

     

     

    PRO-DEX, INC.  
       
    /s/ Alisha K. Charlton  
    Name: Alisha K. Charlton  
    Title: Chief Financial Officer

     

     

     

     

     

     

     

     

    Get the next $PDEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PDEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results

    IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended March 31, 2024Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023, due primarily to an increase in medical device product revenue of $2.8 million offset by a decrease in non-recurring engineering and repair revenue of $736,000 and $635,000 respectively.Gross profit for

    5/2/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Philp Katrina Marie Kramer was granted 3,100 shares, increasing direct ownership by 45% to 2,900 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/24/25 4:00:02 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Van Kirk Richard Lee Jr covered exercise/tax liability with 72 shares, decreasing direct ownership by 0.07% to 99,707 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:46:37 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Director Swenson Nicholas John was granted 1,000 shares, increasing direct ownership by 1% to 97,613 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:45:52 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    SEC Filings

    View All

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    12/19/25 4:00:23 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    11/21/25 4:01:39 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    10/30/25 4:05:26 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Pro-Dex Inc.

    SC 13D - PRO DEX INC (0000788920) (Filed by)

    10/17/23 5:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - PRO DEX INC (0000788920) (Subject)

    2/22/21 4:47:58 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Financials

    Live finance-specific insights

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results

    IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings

    11/2/23 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care